Dr. Albert Oriol on the Updated KarMMa Trial Results
What is the background of the study?
Patients with relapsed and refractory multiple myeloma (RRMM) previously exposed to immunomodulatory agents, proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (mAbs) have poor outcomes with subsequent treatments. In the pivotal KarMMa trial, ide-cel, a BCMA-directed CAR T cell therapy, showed frequent, deep, and durable responses in heavily pretreated patients with RRMM (Munshi NC, et al. N Engl J Med 2021;384:705-716).
In this video:
Dr. Albert Oriol (Institut Català d’Oncologia, Badalona, Spain) discusses the updated KarMMa results which studied Ide-Cel in relapsed and refractory multiple myeloma patients.
Conclusions:
Updated results from the KarMMa trial continue to demonstrate deep, durable responses with ide-cel in heavily pretreated, triple-class–exposed patients with relapsed/refractory multiple myeloma. Efficacy and safety reflect prior reports and support a favorable clinical benefit-risk profile for ide-cel across the target dose levels.
